This article has been updated from a previous version to include comments from Nanosphere.

NEW YORK (GenomeWeb News) – Eppendorf said today that it has initiated an import ban against molecular diagnostics workstations and kits sold by Nanosphere because they allegedly infringe patents owned by Eppendorf that relate to microarray-based products.

The import ban covers any and all imports of Northbrook, Ill.-based Nanosphere's Verigene and Verigene SP systems into any country of the European Union, Eppendorf said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.

Kaiser Health News reports that gene therapies could cost more than a million dollars.

Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.

In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.